We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

102 hedge funds and large institutions have $88.7M invested in Cymabay Therapeutics in 2020 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 32

10% less funds holding

Funds holding: 113 → 102 (-11)

21% less capital invested

Capital invested by funds: $112M → $88.7M (-$23.5M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

36% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 25

Holders
102
Holders Change
-11
Holders Change %
-9.73%
% of All Funds
2.25%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
16
Increased
29
Reduced
32
Closed
25
Calls
$955K
Puts
–
Net Calls
+$955K
Net Calls Change
+$80K

Top Buyers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
+$4.37M
2
IC
Ikarian Capital
Texas
+$3.97M
3
ECM
Engine Capital Management
New York
+$2.11M
4
VC
Vivo Capital
California
+$1.81M
5
JP Morgan Chase
JP Morgan Chase
New York
+$1.28M

Top Sellers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management IV
California
-$4.54M
2
Morgan Stanley
Morgan Stanley
New York
-$3.82M
3
FCMI
Foresite Capital Management III
California
-$2.95M
4
Millennium Management
Millennium Management
New York
-$2.41M
5
Renaissance Technologies
Renaissance Technologies
New York
-$833K
Name Holding Trade Value Shares
Change 		Change in
Stake
VVM
26
Versant Venture Management
California
$805K – – –
N
27
Nuveen
North Carolina
$583K -$654K -389,603 -50%
Charles Schwab
28
Charles Schwab
California
$556K +$9.34K +5,561 +2%
Bank of America
29
Bank of America
North Carolina
$553K +$525K +312,860 +510%
UBS Group
30
UBS Group
Switzerland
$551K +$483K +287,393 +340%
MWNA
31
Marshall Wace North America
New York
$541K +$614K +365,866 New
Two Sigma Advisers
32
Two Sigma Advisers
New York
$521K +$388K +231,000 +191%
Two Sigma Investments
33
Two Sigma Investments
New York
$477K -$111K -66,245 -17%
2L
34
22NW LP
Washington
$438K +$496K +295,676 New
Bank of New York Mellon
35
Bank of New York Mellon
New York
$419K +$3.62K +2,153 +0.8%
Hudson Bay Capital Management
36
Hudson Bay Capital Management
Connecticut
$318K -$185K -110,000 -34%
BFM
37
Boothbay Fund Management
New York
$317K +$360K +214,436 New
Squarepoint
38
Squarepoint
New York
$266K +$95.8K +57,041 +47%
PPA
39
Parametric Portfolio Associates
Washington
$256K +$96.8K +57,663 +50%
Morgan Stanley
40
Morgan Stanley
New York
$232K -$3.82M -2,274,946 -94%
BCM
41
Bridgeway Capital Management
Texas
$229K -$206K -122,600 -44%
Victory Capital Management
42
Victory Capital Management
Texas
$216K +$115K +68,646 +89%
Barclays
43
Barclays
United Kingdom
$204K +$105K +62,598 +83%
AllianceBernstein
44
AllianceBernstein
Tennessee
$203K +$34.6K +20,600 +18%
SCM
45
Sio Capital Management
New York
$196K +$222K +132,474 New
A
46
Abingworth
United Kingdom
$191K – – –
Federated Hermes
47
Federated Hermes
Pennsylvania
$185K +$44.4K +26,451 +27%
Swiss National Bank
48
Swiss National Bank
Switzerland
$175K – – –
Connor, Clark & Lunn Investment Management (CC&L)
49
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$173K +$149K +88,925 +322%
AIM
50
Alambic Investment Management
California
$171K -$87.8K -52,294 -31%
1
2
3 4 5

CBAY Hedge Fund Activity: Q1 2020 in Review

102 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2020, worth a combined $88.7M — down 21% from $112M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of CBAY and 16 opened new positions — a net loss of 9 holders — while 32 trimmed existing stakes and 29 added.

The largest buyer was Deutsche Bank, adding an estimated $4.37M. The largest seller was Foresite Capital Management IV, exiting entirely with an estimated $4.54M sold.

  • 102 institutional investors held Cymabay Therapeutics (CBAY) as of Q1 2020, down from 113 in Q4 2019.
  • Funds reported $88.7M of Cymabay Therapeutics stock for Q1 2020, down 21% quarter-over-quarter.
  • 16 funds opened new Cymabay Therapeutics positions in Q1 2020 and 25 closed out, a net change of -9 holders.
  • The largest Cymabay Therapeutics buyer in Q1 2020 was Deutsche Bank, an estimated $4.37M added.
  • The largest Cymabay Therapeutics seller in Q1 2020 was Foresite Capital Management IV, an estimated $4.54M sold.

Based on aggregated 13F filings for Q1 2020.